IGFBP7 and neoplasm: This means that in our ELISA results, the serum level difference of IGFP7 in LSCC patients compared to the control group was approximately 45% higher than the serum IGFBP7 level difference of IHD patients compared to the population group in the study by Lisowska et al. Due to the small number of patients with IHD in the tumor group of cohorts A and B and the significantly lower fold change in IGFBP7 levels in IHD patients compared to our results in LSCC patients, it can be assumed that the influence of this comorbidity on our ELISA results is probably minimal at worst.